Pfizer mimics pumitamig in gastroesophageal cancers
The company will start a phase 2/3 trial of PF-08634404 in March.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Summit joins the global colorectal fight
The pivotal Harmoni-GI3 study has started enrolling patients.
Pfizer speeds ahead with bispecific development
The company will imminently start its third pivotal trial of PF-08634404.
Lorikeet fails to fly for MacroGenics
The company ditches lorigerlimab in prostate cancer.
